DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
6.45
+0.13 (2.06%)
May 11, 2026, 4:00 PM EDT - Market closed
DiaMedica Therapeutics Employees
DiaMedica Therapeutics had 35 employees as of December 31, 2025. The number of employees increased by 7 or 25.00% compared to the previous year.
Employees
35
Change (1Y)
7
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,002,886
Market Cap
347.55M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 35 | 7 | 25.00% | 35 | 0 |
| Dec 31, 2024 | 28 | 9 | 47.37% | 27 | 1 |
| Dec 31, 2023 | 19 | 3 | 18.75% | 18 | 1 |
| Dec 31, 2022 | 16 | 1 | 6.67% | 16 | 0 |
| Dec 31, 2021 | 15 | 4 | 36.36% | 14 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| Bicycle Therapeutics | 288 |
| Abeona Therapeutics | 226 |
| Nautilus Biotechnology | 130 |
| Niagen Bioscience | 117 |
| Neumora Therapeutics | 96 |
| Lineage Cell Therapeutics | 77 |
| Rezolute | 75 |
DMAC News
- 5 days ago - DiaMedica Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 5 days ago - DiaMedica Therapeutics reports Q1 EPS (19c), consensus (19c) - TheFly
- 5 days ago - DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights - Business Wire
- 12 days ago - DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 - Business Wire
- 25 days ago - DiaMedica Therapeutics Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators - Transcripts
- 6 weeks ago - DiaMedica Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 6 weeks ago - DiaMedica Therapeutics reports FY25 EPS (70c), consensus (68c) - TheFly
- 6 weeks ago - DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights - Business Wire